CD19 and B-cell chronic lymphocytic leukemia: In a clinical study, the second generation CD19 CAR (CTL019) containing anti-CD19 scFv, CD3ζ domain along with 4-1BB co-stimulatory domain revealed robust expansion and long persistence of CTL019 cells along with sustained remissions in patients with relapsed/refractory chronic lymphocytic leukemia CLL (46).